You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨信達生物大漲超13% 24年收入達94.2億元創新高 腫瘤品牌領跑市場
格隆匯 03-27 11:38
中國領先的生物製藥公司信達生物(1801.HK)大幅上漲超13%,高見44.7港元刷新階段新高,成交額明顯放大至超12億港元,總市值727.3億港元。消息上,2024年公司全年總收入同比增長51.8%至人民幣94.2億元創新高,其中產品收入人民幣82.3億元,同比增長43.6%。收入強勁的增長勢頭得益於公司在中國腫瘤領域領先的品牌地位,達伯舒(信迪利單抗注射液)等主要產品持續保持良好的增長勢頭,新產品組合的快速增長貢獻新動力。展望未來,2025年將是公司邁進雙輪驅動和全球創新發展新時期的關鍵元年,將進一步解鎖向上空間,朝着“成爲國際一流的生物製藥公司”的願景穩步邁進。(格隆匯)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account